AI Article Synopsis
- Langerhans cell histiocytosis (LCH) is an uncommon condition that can lead to secondary sclerosing cholangitis.
- A 42-year-old male diagnosed with sclerosing cholangitis showed signs of LCH through a bile duct biopsy and underwent liver transplantation due to rapid disease progression.
- Nearly two years post-transplant, the patient is doing well, with good liver function and no recurrence of LCH.
Article Abstract
Langerhans cell histiocytosis (LCH) is a very rare cause of secondary sclerosing cholangitis. We report the case of a 42-year-old male patient with sclerosing cholangitis and histological evidence of LCH from a bile duct biopsy. Due to rapid disease progression and exhaustion of conservative therapeutic approaches the patient received a liver transplantation. Nearly 2 years after transplantation the patient has a good graft function and no signs of recurrence of the underlying LCH.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00108-021-01148-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The utilisation of biliary organoids for biomedical applications.
Front Bioeng Biotechnol
January 2025
Department of Hepatobiliary Surgery, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou, Hainan, China.
Biliary duct injury, biliary atresia (BA), biliary tract tumors, primary sclerosing cholangitis (PSC), and other diseases are commonly encountered in clinical practice within the digestive system. To gain a better understanding of the pathogenesis and development of these diseases and explore more effective treatment methods, organoid technology has recently garnered significant attention. Organoids are three-dimensional structures derived from stem/progenitor cells that can faithfully mimic the intricate structure and physiological function of tissues or organs .
View Article and Find Full Text PDFPSC and colitis: A complex relationship.
Hepatology
January 2025
I. Department of Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Primary sclerosing cholangitis is one of the most challenging conditions in hepatology, and due to our limited understanding of its pathogenesis, no causal therapies are currently available. While it was long assumed that a minority of people with IBD also develop PSC, which is sometimes labeled an extraintestinal manifestation of IBD, the clinical phenotype, genetic and intestinal microbiota associations strongly argue for PSC-IBD being a distinct form of IBD, existing alongside ulcerative colitis and Crohn's disease. In fact, the liver itself could contribute to intestinal pathology, clinically overt in 60 - 80 % of patients.
View Article and Find Full Text PDFMortality in Autoimmune Liver Disease in Sweden: A Population-Based Cohort Study of 9,654 Patients.
Liver Int
February 2025
Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden.
Background/aims: Epidemiological data on mortality in autoimmune liver diseases (AILDs) are scarce. We examined all-cause and cancer-related mortality in individuals with AILD from Sweden.
Methods: We identified 9654 individuals with AILD (3342 with autoimmune hepatitis (AIH), 3751 with primary biliary cholangitis (PBC), and 2561 with primary sclerosing cholangitis (PSC)) using national Swedish registries between 2001 and 2020.
Statin use is associated with protection against acute cholangitis in patients with primary sclerosing cholangitis: a multi-center retrospective cohort study.
Clin Transl Gastroenterol
January 2025
Division of Gastroenterology & Hepatology, Department of Medicine, Stanford University, Palo Alto, California.
Introduction: Patients with primary sclerosing cholangitis (PSC) are at increased risk for acute cholangitis. The epidemiological risks for cholangitis are poorly studied despite the high morbidity associated with this infection. This study's aim was to understand the impact of statins on acute cholangitis in PSC.
View Article and Find Full Text PDFPrevalence and Bidirectional Association Between Primary Sclerosing Cholangitis and Crohn's disease: A Systematic Review and Meta-Analysis.
Gastroenterol Hepatol
January 2025
The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310005, China. Electronic address:
Purpose: This meta-analysis aimed to evaluating the prevalence of Crohn's disease in primary sclerosing cholangitis (PSC) and the incidence of primary sclerosing cholangitis in Crohn's disease (CD), along with their interrelation.
Methods: An extensive search was conducted in the PubMed and Embase to identify available publications up to December 2023. Studies were included if they reported the prevalence of CD in PSC patients, or vice versa.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!